Association of PDIA4 with clinicopathological characters in
gliomas
According to the hypothesis that PDIA4 plays a critical role in glioma
aggressiveness, we first measured the expression of PDIA4 in glioma
tissues compared with normal brain tissues. The remarkably increased
expression of PDIA4 was observed in both GBM samples and Low-Grade
glioma (LGG) samples (Figure 1A, p<0.001). To further validate this
result, we performed Q-PCR in glioma cell lines. The results documented
that the mRNA expression of PDIA4 was elevated in glioma cell lines when
compared with normal glial cell line (Figure 1B). Moreover, PDIA4
expression was positively correlated with glioma histological grade in
both TCGA and CGGA cohort (Figure 1C). It’s widely recognized mutations
in isocitrate dehydrogenase genes (IDH1 and IDH2) have strong
connections with tumor behaviors in gliomas. Patients with IDH-mutant
(IDH-Mut) histology exhibited better prognosis than IDH-wildtype
(IDH-Wt). Intriguingly, we also observed the elevated expression level
of PDIA4 in IDH-Wt subtype of glioma when compared with IDH-Mut tumors
(Figure 1D). Additionally, we evaluated the expression of PDIA4 in
different patterns of glioma. The results showed higher expression of
PDIA4 in mesenchymal and classical subtypes rather than neural and
proneural subtypes (Figure 1E).